CN108976278A - 一种嵌合分子及其制备和应用 - Google Patents
一种嵌合分子及其制备和应用 Download PDFInfo
- Publication number
- CN108976278A CN108976278A CN201810557353.XA CN201810557353A CN108976278A CN 108976278 A CN108976278 A CN 108976278A CN 201810557353 A CN201810557353 A CN 201810557353A CN 108976278 A CN108976278 A CN 108976278A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- compound according
- aryl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 230000017854 proteolysis Effects 0.000 claims abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 95
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 28
- 125000000304 alkynyl group Chemical group 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 14
- 125000004185 ester group Chemical group 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims description 9
- 108091005625 BRD4 Proteins 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000004442 acylamino group Chemical group 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- -1 small molecule compound Chemical group 0.000 abstract description 37
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 108091005575 Bromodomain-containing proteins Proteins 0.000 abstract description 2
- 102000001805 Bromodomains Human genes 0.000 abstract description 2
- 108091005804 Peptidases Proteins 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract description 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 67
- 230000015572 biosynthetic process Effects 0.000 description 48
- 238000003786 synthesis reaction Methods 0.000 description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000002585 base Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 238000003810 ethyl acetate extraction Methods 0.000 description 23
- 238000010792 warming Methods 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 238000004440 column chromatography Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000007821 HATU Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000012964 benzotriazole Substances 0.000 description 12
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 238000005406 washing Methods 0.000 description 7
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4MTO Natural products CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- QVSITNJKGHUCGD-UHFFFAOYSA-N [O].FC=1C=CC=C(C1)F Chemical compound [O].FC=1C=CC=C(C1)F QVSITNJKGHUCGD-UHFFFAOYSA-N 0.000 description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 0 CC(C[C@]1[C@@](C)*(C)C[C@@]1C)[C@](C)CC* Chemical compound CC(C[C@]1[C@@](C)*(C)C[C@@]1C)[C@](C)CC* 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940125810 compound 20 Drugs 0.000 description 5
- 229940126086 compound 21 Drugs 0.000 description 5
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 5
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229950002366 nafoxidine Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 4
- 229940126657 Compound 17 Drugs 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940127204 compound 29 Drugs 0.000 description 4
- 229940125807 compound 37 Drugs 0.000 description 4
- 229940127573 compound 38 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- NVWVWEWVLBKPSM-UHFFFAOYSA-N 2,4-difluorophenol Chemical class OC1=CC=C(F)C=C1F NVWVWEWVLBKPSM-UHFFFAOYSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- 229910015900 BF3 Inorganic materials 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000790917 Dioxys <bee> Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- ZLKWLYKVKAVOMD-UHFFFAOYSA-N 6-methyl-1h-pyrrolo[2,3-c]pyridin-7-one Chemical compound O=C1N(C)C=CC2=C1NC=C2 ZLKWLYKVKAVOMD-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- ZHUQQFDHUNDJCY-UHFFFAOYSA-N (3-bromo-4-fluorophenyl) carbamate Chemical group C(N)(OC1=CC(=C(C=C1)F)Br)=O ZHUQQFDHUNDJCY-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- NNQDMQVWOWCVEM-UHFFFAOYSA-N 1-bromoprop-1-ene Chemical compound CC=CBr NNQDMQVWOWCVEM-UHFFFAOYSA-N 0.000 description 1
- VGYVBEJDXIPSDL-UHFFFAOYSA-N 2-bromo-4-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1Br VGYVBEJDXIPSDL-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- RTRRWXSWYRXKTG-UHFFFAOYSA-N 2-sulfonyl-3,6-dihydro-1H-pyrrolo[2,3-c]pyridin-7-one Chemical compound S(=O)(=O)=C1CC2=C(C(NC=C2)=O)N1 RTRRWXSWYRXKTG-UHFFFAOYSA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QGHDLJAZIIFENW-UHFFFAOYSA-N 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxy-3-prop-2-enylphenyl)propan-2-yl]-2-prop-2-enylphenol Chemical group C1=C(CC=C)C(O)=CC=C1C(C(F)(F)F)(C(F)(F)F)C1=CC=C(O)C(CC=C)=C1 QGHDLJAZIIFENW-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FRUALZRDEJNPTB-UHFFFAOYSA-N BrC1=CC2=C(C(NC=C2)=O)N1S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound BrC1=CC2=C(C(NC=C2)=O)N1S(=O)(=O)C1=CC=C(C)C=C1 FRUALZRDEJNPTB-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101710126815 Bromodomain-containing protein 4 Proteins 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical class [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种嵌合分子。本发明提供了一种嵌合分子,该分子由目标蛋白的小分子化合物单元、E3泛素连接酶结合单元和连接单元组成,能够与BRD蛋白进行结合,促使BRD蛋白更易被蛋白酶降解,从而起到抑制细胞增殖的作用,可以作为BRD蛋白降解的药物,用于治疗癌症或冠状动脉疾病。
Description
技术领域
本发明属于化合物药物领域,具体涉及一种嵌合分子。
背景技术
现代分子生物学从3个基本层次上调控蛋白的表达水平:首先,在DNA水平,通过基因敲除,从而使目标蛋白的DNA失活;其次,在mRNA水平,通过小分子RNA,与目标蛋白的mRNA结合,从而抑制mRNA的翻译及表达;再次,在蛋白水平,通过对翻译后靶蛋白的修饰,例如甲基化、磷酸化、糖基化等,从而调整靶蛋白的量及活性。本专利中涉及的嵌合分子(PROTAC)是基于蛋白水平,调控靶蛋白的表达,用于治疗疾病。本专利中的BRD4嵌合分子具有异源双功能分子,由目标蛋白(BRD4)、E3泛素连接酶识别基团、连接基团构成;耦合目标的目的是为了与在该分子的配体BRD4结合;E3泛素连接酶识别基团的目的是与靶蛋白结合后,导致靶蛋白泛素化,最终使靶蛋白被蛋白酶体降解.
从基因水平的功能基因的敲除,再到mRNA水平小分子RNA的干扰,较多的生化技术已被用来研究蛋白质表达调控;嵌合分子则在不影响DNA及mRNA的表达的情况下,在蛋白水平上直接调控蛋白表达,因此在伦理学上更容易接受。同时,嵌合分子作为一种新的蛋白调控方法,具有其他方法所不具有的优势,有可能成为基因治疗的一种替代方案。嵌合分子靶向降解功能蛋白,有可能研制成药物,成为新的治疗方法。
发明内容
本发明的目的在于提供一种嵌合分子及其制备和应用。
本发明首先提供了式(Ⅰ)所示的化合物、或其立体异构体、或其药学上可接受的盐、或其溶剂合物:
M-L-N (I)
其中,L是连接单元,M和N上的一个原子分别被连接基团L的一端所取代;
单元M如式(a)或(c)所示:
单元N如式(b)所示:
其中,R1、R2中一个选自卤素、-NH-SO2-R7、氢、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代;
其中,R7选自氢、氰基、硝基、烷基、环烷基、杂环烷基、芳基、杂环芳基;
R1、R2中另一个选自-A-的结构,其中A选自-O-、-COX-或-XCO-、-NH-、-HNCONH-、-NH-SO2-R7、-SO2-或-CH2-,X选自-CH2-、-NH-、-SO2-、-O-、酰氨基、酯基或羰基,A与连接单元L相连;
R3、R4、R6分别独立地选自氢、卤素、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代;
R5选自烷基、烷氧基、氨基、酰氨基、酯基、羰基以及上述基团的任意组合。
进一步地,R1、R2中一个选自卤素、-NH-SO2-R7、、氢,R1、R2中另一个选自-A-的结构,其中A选自-O-、-COX-或-XCO-,X选自-CH2-、-NH-、-SO2-、-O-、酰氨基、酯基或羰基,R7选自氢、氰基、硝基、烷基、环烷基、杂环烷基、芳基、杂环芳基。
进一步地,所述X选自-CH2-、-NH-、-O-、酯基或羰基。
进一步地,所述M结构为式(a1)或式(a2)所示:
其中,A1选自-COX-或-XCO-,X选自-CH2-、-NH-、-O-、酯基或羰基;
R3、R6分别独立地选自氢、卤素、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代;
R7选自氢、氰基、硝基、烷基、环烷基、杂环烷基、芳基、杂环芳基。
进一步地,所述R6选自C1~C4烷基;优选地,所述R6选自甲基。
进一步地,所述R7选自C1~C4烷基;优选地,所述R7为乙基。
进一步地,所述M结构为式(a3)或式(a4)所示:
其中,A1选自-COX-或-XCO-,X选自-CH2-、-NH-、-O-、酯基或羰基;
R3选自氢、卤素、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代。
进一步地,R3选自氢、卤素、烷基。
进一步地,所述M结构为(a5)或式(a6)所示:
其中,A1选自-COX-或-XCO-;X选自-CH2-、-NH-、-O-、酯基或羰基。
进一步地,所述X选自-NH-或-O-。
进一步地,所述M结构为:
进一步地,所述L选自-(CH2CH2OCH2)n-CO-、-(CH2CH2O)n-CH2CO-、-(CH2OCH2CH2CH2O)n-CH2CO-、-(CH2OCH2)n-CO-、-(CH2OCH2CH2)n-CH2CO-或-(CH2CH2OCH2)n-CH2CO-,其中n为0~20的整数。
进一步地,n为1~3的整数。
进一步地,R4选自H或者CH3(S或R)。
进一步地,所述R5选自烷基或氨基。
进一步地,所述N结构为
其中,R4选自H或者CH3(S或R)。
进一步地,所述N结构为(b1)、(b2)或(b3)所示;
进一步地,所述化合物的结构如式(Ⅱ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅲ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅳ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅴ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅵ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅶ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅷ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅸ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(Ⅹ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(ⅩⅠ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(ⅩⅡ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物的结构如式(ⅩⅢ)所示:
L如权利要求12或13所定义。
进一步地,所述化合物为如下化合物之一:
本发明还提供了该化合物、或其立体异构体、或其药学上可接受的盐、或其溶剂合物在制备BRD4抑制剂类或蛋白降解剂类药物上的用途。
进一步地,所述药物是治疗癌症或冠状动脉疾病的药物。
进一步地,所述癌症是前列腺癌、非小细胞肺癌、乳腺癌、黑色素瘤、白血病或直肠癌。
本发明还提供了一种药物组合物,它是以前述的化合物或其立体异构体、或其药学上可接受的盐、或其溶剂合物为活性成分,加上药学上可接受的辅料制备而成的制剂。
关于本发明的使用术语的定义:除非另有说明,本文中基团或者术语提供的初始定义适用于整篇说明书的该基团或者术语;对于本文没有具体定义的术语,应该根据公开内容和上下文,给出本领域技术人员能够给予它们的含义。
“取代”是指分子中的氢原子被其它不同的原子或分子所替换。
碳氢基团中碳原子含量的最小值和最大值通过前缀表示,例如,前缀(Ca~Cb)烷基表明任何含“a”至“b”个碳原子的烷基。因此,例如,(C1~C6)烷基是指包含1~6个碳原子的烷基。
所述C1~C4烷基是指C1、C2、C3、C4的烷基,即具有1~4个碳原子的直链或支链的烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、仲丁基等等。
所述环烷基是指环状烷基,例如环丙基、环丁基、环戊基、环己基等等。
所述卤素是指氟原子、溴原子、氯原子、碘原子。
术语“药学上可接受的”是指某载体、运载物、稀释剂、辅料,和/或所形成的盐通常在化学上或物理上与构成某药物剂型的其它成分相兼容,并在生理上与受体相兼容。
术语“盐”和“可药用的盐”是指上述化合物或其立体异构体,与无机和/或有机酸和碱形成的酸式和/或碱式盐,也包括两性离子盐(内盐),还包括季铵盐,例如烷基铵盐。这些盐可以是在化合物的最后分离和纯化中直接得到。也可以是通过将上述化合物,或其立体异构体,与一定数量的酸或碱适当(例如等当量)进行混合而得到。这些盐可能在溶液中形成沉淀而以过滤方法收集,或在溶剂蒸发后回收而得到,或在水介质中反应后冷冻干燥制得。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为本发明化合物对BRD4蛋白的电泳图谱。
具体实施方式
实施例1、化合物1(2S,4R)-1-((S)-13-叔丁基-1-(4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)-1,11-二氧代-5,9-二氧-2,12-二氮十四烷基-14-羰基)-4-羟基-N-(4-(4-甲基噻唑-5-yl)苯基)四氢吡咯-2-酰胺(1)的合成
(1)中间体1 (E)-2-(5-溴-2-甲氧基-3-硝基吡啶-4-基)-N,N-二甲基乙胺的合成
向装有N,N-二甲基甲酰胺(4L)的10L的反应瓶中加入5-溴-2-甲氧基-4-甲基-3-硝基吡啶(200g,0.8mol),N,N-二甲基甲酰胺二甲基缩醛(571.2g,4.8mol),甲醇锂(0.9g,0.024mol),加热到110℃搅拌反应3个小时。待反应液冷却至室温后,将其倒入冰水(12L)中,充分析出固体后,抽滤,水(1L)洗,烘干。得棕红色固体粉末中间体1(240g),收率98%。
(2)中间体2 4-溴-7-甲氧基-1H-吡咯并[2,3-c]吡啶的合成
向10L的反应瓶中加入溶剂乙酸乙酯(5L),还原铁粉(223g,3.97mol),乙酸(2.3L,39.7mol),升温至80℃后,加入中间体化合物1(240g,0.79mol)。加完后继续于该温度下反应30分钟。冷却,抽滤,旋干,用乙醇(1L)和水(1L)的混合溶剂打浆。抽滤烘干后得中间体化合物2(140g),收率78%。
(3)中间体3 4-溴-7-甲氧基-1-对甲苯磺酰基-1H-吡咯并[2,3-c]吡啶的合成
向5L的反应瓶中加入N,N-二甲基甲酰胺(2L),中间体化合物2(140g,0.62mol)。溶清后,冰水浴下冷却至0℃,并向反应液中加入NaH(40g,60%,0.99mol),控制反应升温不超过10℃。加完NaH停止冒出气泡后,加入对甲苯磺酰氯(177g,0.93mol),室温下搅拌过夜。反应完全后,将反应液倒入6L水中,析出固体,抽滤,固体用200mL乙酸乙酯溶解,加入600mL正己烷,析出固体,抽滤后得中间体化合物3(188g),收率80%。
(4)中间体4 4-溴-1-甲苯磺酰基-1H-吡咯并[2,3-c]吡啶-7(6H)-酮的合成
向5L的反应瓶中加入1,4-二氧六环2L,甲醇(78g,2.45mol)。室温下,向反应瓶中加入乙酰氯(154g,1.96mol)。加入完毕后,继续搅拌1个小时。加入中间体化合物3(188g,0.49mol),并升温至80℃,搅拌过夜。反应完全后,旋干,用300mL甲基叔丁基醚打浆,抽滤后得中间体化合物4(139g),收率77%。
(5)中间体5 4-溴-6-甲基-1-甲苯磺酰基-1H-吡咯并[2,3-c]吡啶-7(6H)-酮的合成
向5L的反应瓶中加入1,4-二氧六环2L,中间体化合物4(79g,0.21mol)、碳酸铯(118g,0.32mol)、碘甲烷(92g,0.64mol)室温下,搅拌过夜。反应完全后,过滤,旋干,得中间体化合物5(75g),收率94%。
(6)中间体6 6-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-1-甲苯磺酰基-1H-吡咯并[2,3-c]吡啶-7(6H)-酮的合成
向2L的反应瓶中加入800mL的1,4-二氧六环,中间体化合物5(40g,0.1mol)、联硼酸频哪醇酯(105g,0.4mol)、醋酸钾(20.4g,0.2mol),氮气置换三次后加入四三苯基磷钯(12g,0.01mol),氮气置换三次,升温至110℃,搅拌过夜。反应完全后,过滤,柱层析得中间体化合物6(40g),收率93%。
(7)中间体8 3-溴-4-(2,4-二氟苯氧基)苯甲酸甲酯的合成
向250mL的反应瓶中加入中间体化合物7(5g,21.5mmol),2,4-二氟苯酚(4.2g,32.3mmol),碳酸铯(12.5g,38.3mmol)以及150mL DMSO,升温至110度,搅拌过夜。反应完全后,加水200mL,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物8(6.2g,收率84%)。
(8)中间体9 (2,4-二氟苯氧基)-3-(6-甲基-7-氧代-1-甲苯磺酰基-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯甲酸甲酯的合成
向100mL的反应瓶中加入中间体化合物8(500mg,1.46mmol),中间体化合物6(750mg,1.75mmol),四三苯基磷钯(168mg,0.146mmol),碳酸钾(400mg,2.9mmol)以及50mLN,N-二甲基甲酰胺和1-2滴水,氮气置换三次,升温至90℃,搅拌过夜。反应完全后,加入50mL水,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物9(370mg,收率45%)。
(9)中间体10 (2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯甲酸的合成:
向50mL的反应瓶中加入中间体化合物9(350mg,0.62mmol),5NKOH,5mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,浓缩除去四氢呋喃,加2N盐酸调PH<3,过滤,水洗涤,固体干燥得中间体化合物10(185mg,75%)。
(10)中间体12 ((2-(烯丙氧基)乙氧基)甲基)苯的合成
向250mL的反应瓶中加入中间体化合物11(10g,66mmol),100ml四氢呋喃,冰浴下,加入氢化钠(1.89g,79mmol),搅拌半小时,加入溴丙烯(8g,66mmol),升温至40℃,搅拌30分钟,硅藻土过滤,乙酸乙酯洗涤,滤液浓缩得中间体化合物12(7.6g,60%)。
(11)中间体13 3-(2-(苄氧基)乙氧基)丙-1-醇的合成
向250ml的反应瓶中加入中间体化合物12(2.5g,13mmol),25mL四氢呋喃,冰浴下,加入硼烷的四氢呋喃溶液(20mL,1mol/L),升温至25度,搅拌2小时,加入饱和醋酸钠水溶液7mL,30%双氧水6mL,继续搅拌1小时。反应完毕后,加入乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物13(1g,收率37%)。
(12)中间体14 2-(3-(2-(苄氧基)乙氧基)丙氧基)乙酸乙酯的合成
向250mL的反应瓶中加入中间体化合物13(1.6g,7.7mmol),15mL二氯甲烷,冰浴下加入重氮乙酸乙酯(0.9g,7.7mmol),加入0.1mL三氟化硼乙醚溶液,搅拌30分钟,反应完毕后,加入10mL水,有机层无水硫酸钠干燥,柱层析得到中间体化合物14(1.36g,收率60%)。
(13)中间体15 2-(3-(2-羟基乙氧基)丙氧基)乙酸乙酯的合成
向100mL反应瓶中加入中间体化合物14(1.3g),0.25mL醋酸,0.2g钯炭,10mL甲醇,氢气置换三次,室温下搅拌5小时。反应完毕后,过滤,浓缩,柱层析得到中间体化合物15(0.77g,收率82%)。
(14)中间体16 2-(3-(2-((甲基磺酰基)氧基)乙氧基)丙氧基)乙酸乙酯的合成
向100mL反应瓶中加入中间体化合物15(0.77g,3.7mmol),三乙胺(560mg,5.55mmol),10mL二氯甲烷,冰浴下加入甲烷磺酰氯(500mg,4.44mol),室温下搅拌2小时,反应完毕后,加入1N HCl调PH<5,二氯甲烷萃取,无水硫酸钠干燥,浓缩,得中间体化合物16直接用于下一步。
(15)中间体17 2-(3-(2-(1,3-二氧代异吲哚啉-2-基)乙氧基)丙氧基)乙酸乙酯的合成
向100mL反应瓶中加入中间体化合物16,邻苯丁二酰亚胺(0.4g),碳酸钾(0.5g),以及10mL N,N-二甲基甲酰胺,升温至95度,搅拌3小时。反应完毕后,加10mL水,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物17(0.7g,两步收率61%)。
(16)中间体18 2-(3-(2-氨基乙氧基)丙氧基)乙酸乙酯的合成
向100mL的反应瓶中加入中间体化合物17(0.7g,2mmol),0.3g水合肼,10mL甲醇,升温至70度,搅拌1小时,反应完毕后,浓缩,加水,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物18(0.36g,收率84%)。
(17)中间体19 2-(3-(2-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯甲酰氨基)乙氧基)丙氧基)乙酸乙酯的合成
向100mL的反应瓶中加入中间体化合物10(200mg,0.5mmol),中间体化合物18(104mg,0.5mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(300mg,0.8mmol),N,N-二异丙基乙胺DIPEA(208mg,1.6mmol),20mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到中间体化合物19(180mg,收率61%)。
(18)中间体20 2-(3-(2-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-苯甲酰氨基)乙氧基)丙氧基)乙酸的合成
向50mL的反应瓶中加入中间体化合物19(180mg,0.3mmol),2N氢氧化锂水溶液(1mL),甲醇2mL,升温至60度,反应完毕后,加2NHCl调pH<4,过滤,得中间体化合物20(150mg,收率88%)。
(19)化合物2的合成:化合物2(2S,4R)-1-((S)-13-叔丁基-1-(4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)-1,11-二氧代-5,9-二氧-2,12-二氮十四烷基-14-羰基)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
向50mL的反应瓶中加中间体化合物20(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到98mg化合物2,淡黄色固体,收率为56%,质谱:质谱982(M+H+)。1H NMR(400MHz,DMSO)δ11.98(s,1H),8.95(s,1H),8.45-8.44(m,1H),8.34-8.33(m,1H),7.85-7.84(m,1H),7.63-7.62(m,1H),7.47-7.36(m,8H),7.07–6.95(m,2H),6.9-6.89(m,1H),6.25(s,1H),5.16(s,1H),4.97–4.85(m,1H),4.53-4.51(m,1H),4.46-4.42(m,1H),4.24(s,1H),,4.01–3.83(m,2H),3.66-3.60(m,10H),3.55(s,3H),2.43(s,3H),2.07–1.97(m,1H),1.92–1.85(m,2H),1.82–1.75(m,1H),1.44-1.38(m,3H),0.91(s,9H).
实施例2、化合物5(2S,4R)-1-((S)-12-叔丁基-1-(4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)-1,10-二氧代-5,8-二氧-2,11-二氮十三烷基-13-羰基)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
同实施例1相同,向50mL的反应瓶中加入中间体化合物22(根据中间体化合物20的合成方法,其中步骤(12)由乙二醇替代中间体化合物13合成)(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mLDMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到95mg化合物5,淡黄色固体,收率为55%,质谱968(M+H+)。1H NMR(400MHz,DMSO)δ12.03(s,1H),8.97(s,1H),8.45-8.41(m,1H),8.34-8.32(m,1H),7.86-7.84(m,1H),7.65-7.63(m,1H),7.48-7.35(m,8H),7.06–6.93(m,2H),6.91-6.89(m,1H),6.27(s,1H),5.17(s,1H),4.98–4.87(m,1H),4.55-4.52(m,1H),4.47-4.45(m,1H),4.25(s,1H),,4.02–3.87(m,2H),3.68-3.63(m,10H),3.53(s,3H),2.41(s,3H),2.06–1.99(m,1H),1.85–1.77(m,1H),1.45-1.39(m,3H),0.93(s,9H).
实施例3、化合物8(2S,4R)-1-((S)-15-叔丁基-1-(4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)-1,13-二氧代-5,8,11-三氧-2,14-二氮十六烷基-16-羰基)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
同实施例1相同,向50mL的反应瓶中加入中间体化合物23(根据中间体化合物20的合成方法,其中步骤(12)由二乙二醇替代中间体化合物13为原料合成)(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到100mg产物8,淡黄色固体,收率为56%,质谱1012(M+H+)。1H NMR(400MHz,DMSO)δ12.01(s,1H),8.99(s,1H),8.43-8.40(m,1H),8.36-8.33(m,1H),7.88-7.85(m,1H),7.66-7.64(m,1H),7.46-7.37(m,8H),7.05–6.98(m,2H),6.93-6.88(m,1H),6.25(s,1H),5.15(s,1H),4.97–4.89(m,1H),4.57-4.53(m,1H),4.48-4.46(m,1H),4.23(s,1H),4.01–3.89(m,2H),3.69-3.65(m,14H),3.51(s,3H),2.47(s,3H),2.08–1.97(m,1H),1.88–1.79(m,1H),1.47-1.37(m,3H),0.96(s,9H).
实施例4、化合物11(2S,4R)-1-((S)-2-(2-(3-(2-((4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)氨基)-2-氧代乙氧基)丙烷)乙酰胺基)-叔丁基)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
(1)中间体24 2-溴-1-(2,4-二氟苯氧基)-4-硝基苯的合成
向250mL反应瓶中加入3-溴-4-氟硝基苯(5.5g,25mmol),2,4-二氟苯酚(5g,38mmol),碳酸铯(12.5g,50mmol)和100mLDMSO,升温至110度,搅拌4小时。反应完毕后,加入200mL水,过滤,干燥得中间体化合物24(5.1g),收率62%。
(2)中间体25 3-溴-4-(2,4-二氟苯氧基)苯胺的合成
向250mL反应瓶中加入中间体化合物24(2g,6mmol),铁粉(1.8g,32mmol),20mL四氢呋喃,20mL乙醇和10mL水,升温至100度,搅拌4小时。反应完毕后,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物25(1.1g,收率62%)。
(3)中间体26 4-(5-氨基-2-(2,4-二氟苯氧基)苯基)-6-甲基-1-对甲苯磺酰-1,6-二氢-7H-吡咯并[2,3-c]吡啶-7-酮的合成
向100mL的反应瓶中加入中间体化合物25(500mg,1.6mmol),中间体化合物6(750mg,1.75mmol),四三苯基磷钯(168mg,0.146mmol),碳酸钾(400mg,2.9mmol)以及50mLN,N-二甲基甲酰胺和1-2滴水,氮气置换三次,升温至90℃,搅拌过夜。反应完全后,加入50mL水,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物26(450mg,收率51.7%)。
(4)中间体27 4-(5-氨基-2-(2,4-二氟苯氧基)苯基)-6-甲基-1,6-二氢-7H-吡咯并[2,3-c]吡啶-7-酮的合成
向50mL的反应瓶中加入中间体化合物26(450mg,0.86mmol),5NKOH,5mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,浓缩除去四氢呋喃,加2N盐酸调PH<3,过滤,水洗涤,固体干燥得中间体化合物27(225mg,71.2%)。
(5)中间体28 2-(3-羟基丙氧基)乙酸乙酯的合成
向250mL的反应瓶中加入丙二醇(10g,131mmol),100mL二氯甲烷,冰浴下加入重氮乙酸乙酯(3g,26mmol),加入三滴三氟化硼乙醚溶液,搅拌30分钟,反应完毕后,加入100mL水,有机层无水硫酸钠干燥,柱层析得到中间体化合物28(1.3g,收率30%)。
(6)中间体29 2-(3-(2-乙氧基-2-氧代乙氧基)丙氧基)乙酸叔丁酯的合成
向250mL的反应瓶中加入中间体化合物28(1.2g,7.4mmol),50mL二氯甲烷,冰浴下加入重氮乙酸乙酯(1.2g,8.4mmol),加入三滴三氟化硼乙醚溶液,搅拌30分钟,反应完毕后,加入50mL水,有机层无水硫酸钠干燥,柱层析得到中间体化合物29(1.1g,收率55%)。
(7)中间体30 2-(3-(2-(叔丁氧基)-2-氧代乙氧基)丙氧基)乙酸的合成
向100mL的反应瓶中加入中间体化合物29(1.1g,4mmol),4N氢氧化钾,10mL水和10mL四氢呋喃,室温搅拌30分钟,反应完毕后,用2NHCl调pH<4,乙酸乙酯萃取,有机层无水硫酸钠干燥,柱层析得到中间体化合物30(800mg,收率71%)。
(8)中间体31 (3-(2-((4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)氨基)-2-氧代乙氧基)丙氧基)乙酸乙酯的合成
向50mL的反应瓶中加入中间体化合物27(240mg,0.8mmol),中间体化合物28(240mg,0.96mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(480mg,1.26mmol),N,N-二异丙基乙胺DIPEA(164mg,1.26mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到中间体化合物31(170mg,收率为40%)。
(9)中间体32 2-(3-(2-((4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4--基)苯基)氨基)-2-氧代乙氧基)丙氧基)乙酸的合成
向50mL的反应瓶中加入中间体化合物31(170mg,0.28mmol),10mL甲酸,升温至40度,搅拌过夜。反应完毕后,浓缩,柱层析得到中间体化合物32(130mg,收率85%)。
(10)化合物11的合成
向50mL的反应瓶中加入中间体化合物32(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到101mg化合物11,淡黄色固体,收率为58%,质谱968(M+H+)。1H NMR(400MHz,DMSO)δ12.02(s,1H),9.79(s,1H),8.98(s,1H),8.44-8.42(m,1H),7.84-7.83(m,1H),7.62-7.61(m,1H),7.49-7.34(m,8H),7.08–6.93(m,2H),6.91-6.9(m,1H),6.28(s,1H),5.14(s,1H),4.95–4.80(m,1H),4.55-4.53(m,1H),4.44-4.43(m,1H),4.28(s,1H),4.06(s,2H),4.01–3.86(m,2H),3.65-3.61(m,6H),3.53(s,3H),2.45(s,3H),2.09–1.99(m,1H),1.94–1.82(m,2H),1.81–1.70(m,1H),1.4-1.36(m,3H),0.89(s,9H).
实施例5、化合物14(2S,4R)-1-((S)-2-(2-(2-(2-((4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)氨基)-2-氧代乙氧基)丙烷)乙酰胺基)-叔丁基)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
向50mL的反应瓶中加入中间体化合物33(根据中间体化合物32的合成方法由乙二醇替代丙二醇为原料合成(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到95mg化合物14,淡黄色固体,收率为54%,质谱955(M+H+)。1H NMR(400MHz,DMSO)δ12.03(s,1H),9.77(s,1H),8.96(s,1H),8.45-8.41(m,1H),7.86-7.85(m,1H),7.63-7.62(m,1H),7.48-7.33(m,8H),7.07–6.95(m,2H),6.93-6.91(m,1H),6.25(s,1H),5.11(s,1H),4.91–4.85(m,1H),4.57-4.51(m,1H),4.46-4.42(m,1H),4.27(s,1H),4.05(s,2H),4.01–3.88(m,2H),3.69-3.62(m,6H),3.51(s,3H),2.47(s,3H),2.05–1.97(m,1H),1.80–1.75(m,1H),1.42-1.38(m,3H),0.92(s,9H).
实施例6、化合物17(2S,4R)-1-((S)-2-叔丁基-14-((4-(2,4-二氟苯氧)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯基)氨基)-4,14-二氧代-6,9,12-三氧-3-氮十三烷基-1-羰基)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
向50mL的反应瓶中加入中间体化合物34(根据中间体化合物32的合成方法由二乙二醇替代丙二醇为原料合成(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到93mg化合物17,淡黄色固体,收率为55%,质谱999(M+H+)。1H NMR(400MHz,DMSO)δ11.98(s,1H),9.79(s,1H),8.91(s,1H),8.47-8.43(m,1H),7.87-7.83(m,1H),7.65-7.61(m,1H),7.49-7.37(m,8H),7.09–6.99(m,2H),6.95-6.92(m,1H),6.26(s,1H),5.13(s,1H),4.93–4.87(m,1H),4.59-4.53(m,1H),4.47-4.45(m,1H),4.29(s,1H),4.07(s,2H),4.03–3.89(m,2H),3.67-3.61(m,10H),3.53(s,3H),2.48(s,3H),2.07–1.99(m,1H),1.83–1.79(m,1H),1.44-1.37(m,3H),0.9(s,9H).
实施例7、化合物29(2S,4R)-1-((S)-2-(2-(3-(2-(4-(4-(乙硫酰胺)-2-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-yl)苯氧基)-3-氟苯氧基)乙氧基)丙烷)乙酰胺)-3,3-二甲基丁基氧代)-4-羟基-N-((S)-1-4-(4-甲基噻唑-5-yl)苯基)乙基)四氢吡咯-2-酰胺的制备
(1)中间体36 N-(4-(2-氟-4-甲氧基苯氧基)-3-(6-甲基-7-氧代-1-对甲苯磺酰-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)乙磺酰胺的合成
向50mL的反应瓶中加入中间体化合物35(根据中间体化合物26的合成方法由2-氟-4-甲氧基苯酚替代2,4-二氟苯酚为原料合成(1g,1.87mmol),三乙胺(283mg,2.8mmol)和20mL二氯甲烷,冰浴下,加入乙基磺酰氯(360mg,2.8mmol)。反应完毕后,加20mL水,二氯甲烷萃取,无水硫酸钠干燥,柱层析后得到中间体化合物36(0.95g,收率84%)。
(2)中间体37 N-(4-(2-氟-4-甲氧基苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)乙磺酰胺的合成
向50mL的反应瓶中加入中间体化合物36(0.9g,1.43mmol),5NKOH,5mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,浓缩除去四氢呋喃,加2N盐酸调PH<3,过滤,水洗涤,固体干燥得中间体化合物37(600mg,88%)。
(3)中间体38 N-(4-(2-氟-4-羟基苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)乙磺酰胺的合成
向50mL的反应瓶中加入中间体化合物37(0.6g,1.27mmol),HBr水溶液10mL,10mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物38(480mg,82.7%)。
(4)中间体39 2-(3-(2-(4-(4-(乙基磺酰氨基)-2-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]苯氧基)-3-氟苯氧基)乙氧基)丙氧基)乙酸乙酯的合成
向50mL的反应瓶中加入中间体化合物38(400mg,0.87mmol),中间体化合物15(180mg,0.87mmol),三苯基磷(262mg,1mmol),冰浴下加入偶氮二甲酸二异丙酯(220mg,1.1mmol),搅拌4小时。反应完全后,乙酸乙酯萃取,无水硫酸钠干燥,柱层析得中间体化合物39(220mg,41%)。
(5)中间体40 2-(3-(2-(4-(4-(乙基磺酰胺基)-2-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯氧基)-3-氟苯氧基)乙氧基)丙氧基)乙酸的合成
向50mL的反应瓶中加入中间体化合物39(220mg,0.34mmol),5NKOH,5mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,浓缩除去四氢呋喃,加2N盐酸调PH<3,过滤,水洗涤,固体干燥得中间体化合物40(150mg,71%)。
(6)化合物29的合成
向50mL的反应瓶中加入中间体化合物40(100mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到89mg产物29,淡黄色固体,收率为51%,质谱1045(M+H+)。1H NMR(400MHz,DMSO)δ12.02(s,1H),9.58(s,1H),8.98(s,1H),8.44-8.42(m,1H),7.84-7.83(m,1H),7.62-7.61(m,1H),7.49-7.34(m,8H),7.08–6.93(m,2H),6.91-6.9(m,1H),6.28(s,1H),5.14(s,1H),4.95–4.80(m,1H),4.55-4.53(m,1H),4.44-4.43(m,1H),4.28(s,1H),4.06(s,2H),4.01–3.86(m,2H),3.65-3.61(m,8H),3.53(s,3H),3.07-3.04(m,2H),2.45(s,3H),2.09–1.99(m,1H),1.94–1.82(m,2H),1.81–1.70(m,1H),1.4-1.36(m,3H),1.25-1.23(m,3H),0.89(s,9H).
实施例8、化合物37(2S,4R)-1-S)-13-(叔丁基)-1-4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)氨基)-1,11二氧代-5,9-二氧杂-2,12-二氮十四烷-14酰基)-4-羟基N-((S)-1-(4-(4-甲基噻唑-5-基)苯基)乙基)吡咯烷-2-甲酰胺的制备
(1)中间体41 2-(3-(2-(3-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-1-甲苯磺酰基-6,7-二氢-1H-吡咯并[2,3-3-c]吡啶-4-基)苯基)脲基)乙氧基)丙氧基)乙酸乙酯的合成
向50mL的反应瓶中加入三光气(88mg,0.296mmol),5mL四氢呋喃,冰浴下加入中间体化合物18(220mg,1.07mmol)和三乙胺(60mg,0.6mmol)的5mL四氢呋喃溶液,搅拌30分钟,加入中间体化合物26(100mg,0.19mmol),搅拌1小时。反应完全后,乙酸乙酯萃取,无水硫酸钠干燥,柱层析后得中间体化合物41(56mg,38.9%)。
(2)中间体42 2-(3-(2-(3-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)脲基)乙氧基)丙氧基)乙酸的合成
向50mL的反应瓶中加入中间体化合物41(56mg,0.074mmol),5NKOH,5mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,浓缩除去四氢呋喃,加2N盐酸调PH<3,过滤,水洗涤,固体干燥得中间体化合物42(35mg,83%)。
(3)化合物37的合成
向50mL的反应瓶中加入中间体化合物42(42mg,0.074mmol),中间体化合物21(根据US20170327469合成)(36mg,0.074mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(38mg,0.1mmol),N,N-二异丙基乙胺DIPEA(26mg,0.2mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到32mg产物37,淡黄色固体,收率为44%,质谱997(M+H+)。1H NMR(400MHz,DMSO)δ12.00(s,1H),9.45(s,1H),8.98(s,1H),8.49-8.48(m,1H),7.65-7.64(m,1H),7.46–7.16(m,8H),7.02-7.01(m,1H),6.93-6.92(m,3H),6.86-6.84(m,2H),6.26(s,1H),4.96–4.83(m,1H),4.54-4.53(m,1H),4.46-4.45(m,2H),4.28(s,2H),4.00–3.84(m,2H),3.66–3.47(m,13H),2.45(s,3H),2.1-2.08(m,1H),1.84–1.71(m,1H),1.36-1.33(m,3H),0.90(s,9H).
实施例9、化合物38(2S,4R)-1-((S)-2-(2-(3-(2-(N-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6-1,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)乙基磺酰氨基)乙氧基)丙氧基)乙酰氨基)-3,3-二甲基丁酰基)-4-羟基-N-((S)-1-(4-(4-甲基噻唑-5-基)苯基)乙基)吡咯烷-2-甲酰胺的制备
(1)中间体43 N-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-1-对甲苯磺酰-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)乙磺酰胺的合成
向50mL的反应瓶中加入中间体化合物26(1g,1.92mmol),三乙胺(283mg,2.8mmol)和20mL二氯甲烷,冰浴下,加入乙基磺酰氯(360mg,2.8mmol)。反应完毕后,加20mL水,二氯甲烷萃取,无水硫酸钠干燥,柱层析后得到中间体化合物43(0.9g,收率77%)。
(2)中间体44 2-(3-(2-(N-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-1-甲苯磺酰基-6,7-二氢-1H-吡咯并[2,3-3-c]吡啶-4-基)苯基)乙基磺酰氨基)乙氧基)丙氧基)乙酸乙酯的合成
向50mL的反应瓶中加入中间体化合物43(150mg,0.244mmol),中间体化合物16(70mg,0.244mmol),碳酸铯(163mg,0.5mmo),10mg碘化钾和20mLDMSO,10mL水,升温至100度,搅拌过夜。反应完毕后,加20mL水,乙酸乙酯萃取,无水硫酸钠干燥,柱层析后得到中间体化合物44(110mg,收率57%)。
(3)中间体45 2-(3-(2-(N-(4-(2,4-二氟苯氧基)-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,3-c]吡啶-4-基)苯基)乙基磺酰氨基)乙氧基)丙氧基)乙酸的合成
向50mL的反应瓶中加入中间体化合物44(110mg,0.137mmol),5NKOH,5mL四氢呋喃,升温至80℃,搅拌4小时。反应完全后,浓缩除去四氢呋喃,加2N盐酸调PH<3,过滤,水洗涤,固体干燥得中间体化合物45(46mg,54%)。
(4)化合物38的合成
向50mL的反应瓶中加入中间体化合物45(46mg,0.074mmol),中间体化合物21(根据US20170327469合成)(36mg,0.074mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(38mg,0.1mmol),N,N-二异丙基乙胺DIPEA(26mg,0.2mmol),10mL DMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到23mg产物37,淡黄色固体,收率为29.6%,质谱1046(M+H+)。1H NMR(400MHz,DMSO)δ11.98(s,1H),8.91(s,1H),8.42-8.4(m,1H),7.81-7.8(m,1H),7.65-7.63(m,1H),7.45-7.31(m,8H),7.02–6.91(m,2H),6.93-6.91(m,1H),6.24(s,1H),5.19(s,1H),4.91–4.81(m,1H),4.59-4.55(m,1H),4.47-4.45(m,1H),4.24(s,1H),4.01(s,2H),4.0–3.89(m,2H),3.67-3.62(m,8H),3.55(s,3H),3.09-3.01(m,2H),2.47(s,3H),2.05–1.93(m,1H),1.97–1.89(m,2H),1.85–1.73(m,1H),1.45-1.39(m,3H),1.29-1.25(m,3H),0.93(s,9H).
实施例10、化合物39(2S,4R)-1-((S)-13-(叔丁基)-1-(4-氟-3-(6-甲基-7-氧代-6,7-二氢-1H-吡咯并[2,1,3-c]吡啶-4-基)苯基)-1,11二氧代-5,9-二氧杂-2,12-二氮十四烷-14酰基)-4-羟基-N-((S)-1-(4-(4-甲基噻唑-5-基)苯基)乙基)吡咯烷-2-甲酰胺的合成
向50mL的反应瓶中加入中间体化合物46(根据中间体化合物20的合成方法由3-溴-4-氟苯甲酸甲酯替代中间体化合物8为原料合成)(78mg,0.18mmol),中间体化合物21(根据US20170327469合成)(84mg,0.18mmol),2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯HATU(76mg,0.2mmol),N,N-二异丙基乙胺DIPEA(52mg,0.4mmol),10mLDMF,室温下搅拌过夜,加入10mL水,乙酸乙酯萃取,无水硫酸钠干燥,浓缩,柱层析,得到58mg产物39,淡黄色固体,收率为37.5%,质谱858(M+H+)。1H NMR(400MHz,DMSO)δ12.14(s,1H),8.98(s,1H),8.60-8.58(m,1H),8.44-8.43(m,1H),8.02-8.01(m,1H),7.95–7.85(m,1H),7.49–7.26(m,10H),6.16(s,1H),5.14-5.13(m,1H),4.95–4.80(m,1H),4.53-4.52(m,1H),4.44-4.42(m,1H),4.28(s,1H),3.89-3.88(m,2H),3.59(s,3H),3.55–3.43(m,9H),2.45(s,4H),2.04-2.03(m,1H),1.85–1.69(m,1H),1.36-1.34(m,3H),0.92(s,9H).
以下通过试验例来说明本发明的有益效果。
试验例1、本发明化合物对CWR22RV1细胞增殖抑制作用的生物学测定
(1)实验材料:
CWR22RV1细胞(中国科学院细胞库,TCHu100)
FBS(Gibco,Cat.No.10099-141)
0.01M PBS(Biosharp,Cat.No.162262)
RIPM1640(Hyclone,Cat.No.308090.01)
青霉素-链霉素溶液(Hyclone,Cat.No.SV30010)
Cell counting kit-8(Signalway Antibody,Cat.No.CP002)
DMSO(Sigma,Cat.No.D5879)
离心管,15ml(Excell Bio,Cat.No.CS015-0001)
培养皿,(Excell Bio,Cat.No.CS016-0128)
96-well细胞培养簇(Corning,Cat.No.3599)
(2)实验方法
A.缓冲液配制
B.实验步骤
①CWR22RV1细胞用细胞培养液传代培养,取生长状态良好的细胞接种于96孔板,每孔80μL,每孔细胞数为1500,于37℃,5%CO2细胞孵育箱中培养过夜。
②将药物用二甲基亚砜(DMSO)配置成30mM的储存液。临用前再用DMSO稀释3倍,再按3倍梯度稀释,得到9个浓度梯度,再用培养液将各浓度的化合物稀释200倍(以此保证培养体系中DMSO浓度为0.1%),每个浓度做2个孔重复。取20μL稀释好的化合物加到细胞培养孔(终浓度为10μM,3.3μM,1.1μM…),轻轻振荡混匀。另外设置3个只加细胞的阴性对照孔和3个只加培养液的空白对照孔(6孔各加20μL培养液稀释200倍的DMSO)。
(3)结果检测
①培养6天后,每孔加10μL CCK-8,于37℃,5%CO2细胞孵育箱中继续培养2.5小时。
②用多功能酶标仪在450nm处测定吸光度(OD值)。
③数据用软件GraphPad Prism6中Dose-response-inhibition方程分析,得出IC50值。
本发明化合物对CWR22RV1的活性抑制的IC50(nM),结果如表1所示。
表1 化合物对CWR22RV1的活性抑制的IC50
试验例2、本发明化合物BRD4(Bromodomain containing protein 4)蛋白表达生物学测定
(1)实验材料
CWR22RV1细胞(中国科学院细胞库,TCHu100)
FBS(Gibco,Cat.No.10099-141)
0.01M PBS(Biosharp,Cat.No.162262)
RIPM1640(Hyclone,Cat.No.308090.01)
青霉素-链霉素溶液(Hyclone,Cat.No.SV30010)
DMSO(Sigma,Cat.No.D5879)
离心管,15ml(Excell Bio,Cat.No.CS015-0001)
培养皿,(Excell Bio,Cat.No.CS016-0128)
6-well细胞培养簇(Corning,Cat.No.3516)
RIPA裂解液缓冲液(Beyotime,Cat.No.P0013B)
蛋白质缓冲缓冲液(Beyotime,Cat.No.P0015L)
BCA蛋白质定量检测试剂盒(Beyotime,Cat.No.P0012)
SDS-PAGE凝胶制备试剂盒(成都佰和科技有限公司,Cat.No.PG112)
抗β-微管蛋白小鼠单克隆抗体(Zen Bioscience,Cat.No.200608)
Anti-BRD4(E2A7X)兔单克隆抗体(CST,Cat.No.13440)
Peroxidase Affinipure(HRP)山羊抗小鼠IgG(Zen Bioscience,Cat.No.511103)
Peroxidase Affinipure(HRP)山羊抗小鼠IgG(Zen Bioscience,Cat.No.511203)
TBST(Biosharp,Cat.No.BL601A)
ECL化学发光试剂盒(Beyotime,Cat.No.P0018)
(2)实验方法
A.缓冲液配制
B.实验步骤
①CWR22RV1细胞用细胞培养液传代培养后,取生长状态良好的细胞接种于6孔板,每孔2ml,每孔细胞数为100万,于37℃,5%CO2细胞孵育箱中培养过夜。
②将药物用二甲基亚砜(DMSO)配置成30mM的储存液。临用前再用DMSO稀释3倍,取2μl稀释好的化合物加到细胞培养孔(以此保证培养体系中DMSO浓度为0.1%),每个浓度做2个孔重复,轻轻振荡混匀。另外设置阴性对照孔(加等量DMSO)和阳性对照孔。
③培养24小时后,用RIPA细胞裂解液裂解细胞,提取蛋白,用BCA试剂盒测蛋白浓度。加5倍浓缩的蛋白上样缓冲液,100℃加热5分钟后样品放-20℃保存。
④每孔蛋白量为30μg的蛋白量上样到聚丙烯酰胺凝胶,进行电泳。
⑤蛋白质从聚丙烯酰胺凝胶转移到PVDF膜上,加5%脱脂牛奶室温封闭1小时,一抗(Anti-BRD4(E2A7X)rabbit mAb和Anti-β-Tubulin Mouse mAb)4℃孵育过夜,TBST溶液洗膜三次每次10分钟,二抗(辣根过氧化物酶标记羊抗小鼠IgG)室温孵育2小时,再用TBST溶液洗膜三次每次10分钟。
(3)结果检测
最后加ECL显色液显色,用自动化学发光仪拍照,收集图片,分析。本发明化合物对BRD4蛋白的降解,结果如图1所示。
从图1可以看出,本发明提供的化合物对22Rv1细胞增殖具有很好的抑制作用,抑制效果尤其好,说明本发明化合物可以制备成为抗肿瘤药物,特别是治疗前列腺癌的药物。
综上,本发明提供了一种嵌合分子,该分子由目标蛋白的小分子化合物单元、E3泛素连接酶结合单元和连接单元组成,能够与BRD蛋白进行结合,促使BRD蛋白更易被蛋白酶降解,从而起到抑制细胞增殖的作用,可以作为BRD蛋白降解的药物,用于治疗癌症或冠状动脉疾病。
Claims (34)
1.式(Ⅰ)所示的化合物、或其立体异构体、或其药学上可接受的盐、或其溶剂合物:
M-L-N (I)
其中,L是连接单元,M和N上的一个原子分别被连接基团L的一端所取代;
单元M如式(a)或(c)所示:
单元N如式(b)所示:
其中,R1、R2中一个选自卤素、-NH-SO2-R7、氢、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代;
其中,R7选自氢、氰基、硝基、烷基、环烷基、杂环烷基、芳基、杂环芳基;
R1、R2中另一个选自-A-的结构,其中A选自-O-、-COX-或-XCO-、-NH-、-HNCONH-、-NH-SO2-R7、-SO2-或-CH2-,X选自-CH2-、-NH-、-SO2-、-O-、酰氨基、酯基或羰基,A与连接单元L相连;
R3、R4、R6分别独立地选自氢、卤素、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代;
R5选自烷基、烷氧基、氨基、酰氨基、酯基、羰基以及上述基团的任意组合。
2.根据权利要求1所述化合物,其特征在于:R1、R2中一个选自卤素、-NH-SO2-R7、、氢,R1、R2中另一个选自-A-的结构,其中A选自-O-、-COX-或-XCO-,X选自-CH2-、-NH-、-SO2-、-O-、酰氨基、酯基或羰基,R7选自氢、氰基、硝基、烷基、环烷基、杂环烷基、芳基、杂环芳基。
3.根据权利要求2所述化合物,其特征在于:所述X选自-CH2-、-NH-、-O-、酯基或羰基。
4.根据权利要求1所述化合物,其特征在于:所述M结构为式(a1)或式(a2)所示:
其中,A1选自-COX-或-XCO-,X选自-CH2-、-NH-、-O-、酯基或羰基;
R3、R6分别独立地选自氢、卤素、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代;
R7选自氢、氰基、硝基、烷基、环烷基、杂环烷基、芳基、杂环芳基。
5.根据权利要求4所述化合物,其特征在于:所述R6选自C1~C4烷基;优选地,所述R6选自甲基。
6.根据权利要求4所述化合物,其特征在于:所述R7选自C1~C4烷基;优选地,所述R7为乙基。
7.根据权利要求1所述化合物,其特征在于:所述M结构为式(a3)或式(a4)所示:
其中,A1选自-COX-或-XCO-,X选自-CH2-、-NH-、-O-、酯基或羰基;
R3选自氢、卤素、氰基、硝基、烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基,其中所述的烷基、烯基、炔基、环烷基、杂环烷基、芳基或杂环芳基分别独立地任选进一步被一个或多个选自氘原子、卤素、氰基、硝基、氧代基、烷基、卤代烷基、羟烷基、烯基、炔基、环烷基、杂环烷基、芳基、杂环芳基的取代基所取代。
8.根据权利要求7所述化合物,其特征在于:R3选自氢、卤素、烷基。
9.根据权利要求1所述化合物,其特征在于:所述M结构为(a5)或式(a6)所示:
其中,A1选自-COX-或-XCO-;X选自-CH2-、-NH-、-O-、酯基或羰基。
10.根据权利要求9所述化合物,其特征在于:所述X选自-NH-或-O-。
11.根据权利要求10所述化合物,其特征在于:所述M结构为:
12.根据权利要求1所述化合物,其特征在于:所述L选自-(CH2CH2OCH2)n-CO-、-(CH2CH2O)n-CH2CO-、-(CH2OCH2CH2CH2O)n-CH2CO-、-(CH2OCH2)n-CO-、-(CH2OCH2CH2)n-CH2CO-或-(CH2CH2OCH2)n-CH2CO-,其中n为0~20的整数。
13.根据权利要求12所述化合物,其特征在于:n为1~3的整数。
14.根据权利要求1所述化合物,其特征在于:R4选自H或者CH3(S或R)。
15.根据权利要求1所述化合物,其特征在于:所述R5选自烷基或氨基。
16.根据权利要求1所述化合物,其特征在于:所述N结构为
其中,R4选自H或者CH3(S或R)。
17.根据权利要求16所述化合物,其特征在于:所述N结构为(b1)、(b2)或(b3)所示;
18.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅱ)所示:
L如权利要求12或13所定义。
19.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅲ)所示:
L如权利要求12或13所定义。
20.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅳ)所示:
L如权利要求12或13所定义。
21.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅴ)所示:
L如权利要求12或13所定义。
22.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅵ)所示:
L如权利要求12或13所定义。
23.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅶ)所示:
L如权利要求12或13所定义。
24.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅷ)所示:
L如权利要求12或13所定义。
25.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅸ)所示:
L如权利要求12或13所定义。
26.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(Ⅹ)所示:
L如权利要求12或13所定义。
27.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(ⅩⅠ)所示:
L如权利要求12或13所定义。
28.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(ⅩⅡ)所示:
L如权利要求12或13所定义。
29.根据权利要求1所述化合物,其特征在于:所述化合物的结构如式(ⅩⅢ)所示:
L如权利要求12或13所定义。
30.根据权利要求1所述化合物,其特征在于:所述化合物为如下化合物之一:
31.权利要求1-30任一项所述的化合物、或其立体异构体、或其药学上可接受的盐、或其溶剂合物在制备BRD4抑制剂或蛋白降解剂类药物上的用途。
32.根据权利要求31所述的用途,其特征在于:所述药物是治疗癌症或冠状动脉疾病的药物。
33.根据权利要求32所述的用途,其特征在于:所述癌症是前列腺癌、非小细胞肺癌、乳腺癌、黑色素瘤、白血病或直肠癌。
34.一种药物组合物,其特征在于:它是以权利要求1-30任一项所述的化合物或其立体异构体、或其药学上可接受的盐、或其溶剂合物为活性成分,加上药学上可接受的辅料制备而成的制剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710415310 | 2017-06-05 | ||
CN2017104153103 | 2017-06-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108976278A true CN108976278A (zh) | 2018-12-11 |
CN108976278B CN108976278B (zh) | 2021-04-06 |
Family
ID=64540499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810557353.XA Active CN108976278B (zh) | 2017-06-05 | 2018-06-01 | 一种嵌合分子及其制备和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108976278B (zh) |
WO (1) | WO2018223909A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110143961A (zh) * | 2019-06-27 | 2019-08-20 | 江苏省中医药研究院 | 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物 |
CN111944012A (zh) * | 2019-05-17 | 2020-11-17 | 成都海创药业有限公司 | 一种芳香胺类靶向ar和bet的蛋白降解嵌合体化合物及用途 |
CN115109047A (zh) * | 2021-09-08 | 2022-09-27 | 中国科学院化学研究所 | 一种基于protac设计的铁死亡诱导剂 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3693369A3 (en) | 2016-04-15 | 2020-09-09 | AbbVie Inc. | Bromodomain inhibitors |
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
CA3110267A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
KR20220032568A (ko) | 2019-06-25 | 2022-03-15 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104136435A (zh) * | 2011-12-30 | 2014-11-05 | 艾伯维公司 | 溴结构域抑制剂 |
CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
CN105085620A (zh) * | 2015-06-25 | 2015-11-25 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
WO2016077380A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Substituted pyrrolopyridines as inhibitors of bromodomain |
WO2016118666A1 (en) * | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
CN106749513A (zh) * | 2017-01-23 | 2017-05-31 | 中国药科大学 | 基于vhl配体诱导bet降解的双功能分子及其制备和应用 |
-
2018
- 2018-06-01 WO PCT/CN2018/089652 patent/WO2018223909A1/zh active Application Filing
- 2018-06-01 CN CN201810557353.XA patent/CN108976278B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104136435A (zh) * | 2011-12-30 | 2014-11-05 | 艾伯维公司 | 溴结构域抑制剂 |
CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
WO2016077380A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Substituted pyrrolopyridines as inhibitors of bromodomain |
WO2016118666A1 (en) * | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
CN105085620A (zh) * | 2015-06-25 | 2015-11-25 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
WO2017030814A1 (en) * | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
CN106749513A (zh) * | 2017-01-23 | 2017-05-31 | 中国药科大学 | 基于vhl配体诱导bet降解的双功能分子及其制备和应用 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111944012A (zh) * | 2019-05-17 | 2020-11-17 | 成都海创药业有限公司 | 一种芳香胺类靶向ar和bet的蛋白降解嵌合体化合物及用途 |
WO2020233512A1 (zh) * | 2019-05-17 | 2020-11-26 | 成都海创药业有限公司 | 一种芳香胺类靶向ar和bet的蛋白降解嵌合体化合物及用途 |
CN111944012B (zh) * | 2019-05-17 | 2023-08-29 | 海创药业股份有限公司 | 一种芳香胺类靶向ar和bet的蛋白降解嵌合体化合物及用途 |
CN110143961A (zh) * | 2019-06-27 | 2019-08-20 | 江苏省中医药研究院 | 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物 |
CN110143961B (zh) * | 2019-06-27 | 2022-03-29 | 江苏省中医药研究院 | 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物 |
CN115109047A (zh) * | 2021-09-08 | 2022-09-27 | 中国科学院化学研究所 | 一种基于protac设计的铁死亡诱导剂 |
CN115109047B (zh) * | 2021-09-08 | 2024-02-20 | 中国科学院化学研究所 | 一种基于protac设计的铁死亡诱导剂 |
Also Published As
Publication number | Publication date |
---|---|
WO2018223909A1 (zh) | 2018-12-13 |
CN108976278B (zh) | 2021-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108976278A (zh) | 一种嵌合分子及其制备和应用 | |
TWI787620B (zh) | 唑磺醯胺衍生物 | |
AU2019392231B2 (en) | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound | |
CN105121432B (zh) | 作为激酶抑制剂的杂环酰胺 | |
CN114072207A (zh) | 双环化合物 | |
AU2009298981B2 (en) | 8-substituted isoquinoline derivative and use thereof | |
CN104903310B (zh) | 可用于治疗疼痛的双环脲、硫脲、胍及氰基胍化合物 | |
DK2890683T3 (en) | MERGED BICYCLIC SULFAMOYL DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B | |
CN107624113A (zh) | 作为HBsAg(HBV表面抗原)和HBV DNA生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物 | |
CN103694236B (zh) | 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物 | |
CN110291084A (zh) | 用于治疗癌症的组合物和方法 | |
CN109311864A (zh) | 杂芳基取代的吡啶及使用方法 | |
US20070037796A1 (en) | 7-Phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) | |
CN107148417A (zh) | 苯并氮杂*磺酰胺化合物 | |
WO2002032872A1 (en) | Nitrogenous aromatic ring compounds | |
KR20080067694A (ko) | 키나제 억제제로서 유용한 아미노피리미딘 | |
CN105017256A (zh) | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 | |
CN110475785A (zh) | 肽化合物及其制造方法、筛选用组合物以及肽化合物的选择方法 | |
CN108341813A (zh) | 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途 | |
WO2019089670A1 (en) | Alkene compounds as farnesoid x receptor modulators | |
TW201348213A (zh) | 喹唑啉二酮衍生物 | |
WO2020207260A1 (zh) | 一种cdk激酶抑制剂及其应用 | |
CN105712998A (zh) | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 | |
JP2022533147A (ja) | 芳香族アミン類のar及びbetを標的とするタンパク質分解キメラ化合物及び使用 | |
CN117545749A (zh) | 一种蛋白降解剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: No.2 and No.3, floor 4, building 1, Rongyao building, No.5 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610000 Applicant after: Haichuang Pharmaceutical Co., Ltd Address before: No.1, floor 4, building a, Rongyao building, No.5 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610000 Applicant before: Chengdu Haichuang Pharmaceutical Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |